Alzheimer’s Disease

Alzheimer’s Disease

Volumn , Issue , 2011, Pages 1-145

  Lu, Linda C ^a   Bludau, Juergen H ^a   Silver, Julie K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85189806067     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (89)

1. Altman, Lawrence. “The Doctor’s World; A Recollection of Early Questions About Reagan’s Health.” New York Times, June 15, 2004. http://www.nytimes.com/2004/06/15/health/the-doctor-s-world-a-recollection-of-early-questions-about-reagan-s-health. html?sec=&spon=&pagewanted=all.
2. Alzheimer’s Association. Alzheimer’s Disease facts and figures. Alzheimers Dement 2009 May; 5(3): 234-70.
3. Alzheimer’s Association. Alzheimer’s Disease facts and figures. Alzheimers Dement 2010 March; 6(2): 158-94.
4. Alzheimer’s Association: Recommendations to Update Diagnostic Criteria, accessible at http://www.alz.org/research/diagnostic%5Fcriteria/.
5. Alzheimer’s Association and National Alliance for Caregiving. FamiliesCare: Alzheimer’s Caregiving in the United States, 2004, accessible at www.alz.org.
6. American Heart Association: About Cholesterol, accessible at http://www.americanheart. org/presenter.jhtml?identifier=3046105.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (IV-TR). 4th edition-text revised. Washington, D.C., 2000.
8. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004 May; 61(5): 661-66.
9. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel nueroprotector and a cognition enhancer. Ann NY Acad Sci 2001; 939: 425-35.
10. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer’s disease in type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? BST 2005; 33: 1041-44.
11. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006 Jan 25; 1: CD00593.
12. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009 Jan 21; 1: CD003120.
13. Boller F, Forbes MM. History of dementia and dementia in history: An overview. Journal of the Neurological Sciences 1998; 158: 125-33.
14. Canon, Lou. “Actor, Governor, President, Icon.” Washington Post, June 6, 2004, page A1.
15. Center for Disease Control: Traumatic Brain Injury, accessible at http://www.cdc.gov/ncipc/factsheets/tbi.htm.
16. Centers for Medicare and Medicaid Services, accessible at https://www.cms.gov/.
17. Cochrane JJ, et al. The mental health of informal caregivers in Ontario: An epidemiological survey. Am J Public Health 1997; 87: 2002-7.
18. Corkin S. What’s new with the amnesic patient H.M.? Nat Rev Neurosci 2002 Feb; 3(2): 153-60.
19. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer’s disease. Neurobiology of Disease 2009; 35: 128-40.
20. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269: 2386.
21. Devore EE, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutri 2009 Jul; 90(1): 170-76.
22. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behavior, and global function in patients with mild-to-moderate Alzheimer’s disease: A randomized, double-blind, placebo-controlled study. Lancet 2008; 372(9634): 207-15.
23. Exley C, Esiri MM. Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UL. J Neurol Neurosurg Psychiatry 2006; 77: 977-79.
24. Féart C, Samieri C, Rondeau V, et al. Adherence to the Mediterranean diet, cognitive decline, and risk of dementia. JAMA 2009; 302(6): 638-48.
25. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 2010; 74: 956-64.
26. Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer’s disease and related disorders. Neurology 2009; 73: 180-85.
27. Fischer P, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007; 68: 288-91.
28. Folstein MF, Folstein, SE, McHugh, PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189.
29. Food and Drug Administration: Antipsychotics, Conventional and Atypical, accessible at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm110212.htm.
30. Franklin Institute. Blood Vessels in the Human Heart, accessible at http://www.fi.edu/learn/heart/vessels/vessels.html.
31. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004 Jun; (6): 343-53.
32. Frisardi V, et al. Aluminum in the diet and Alzheimer’s disease: from current epidemiology to possible disease-modifying treatment. J Alzheimers Dis 2010 Apr; 20(1): 17-30.
33. Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006 Feb; 63(2): 168-74.
34. Gazzaley AH, Weiland NG, McEwen BS, Morrison JH. Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J Neurosci 1996 Nov 1; 16(21): 6830-38.
35. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology 1995 Mar; 45(3 Pt 1): 461-66.
36. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23: 542-49.
37. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13-17.
38. Herbert LE, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22.
39. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev 2009 Jan 21; 1: CD003799.
40. Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opin Investig Drugs 2009 August; 18(8): 1147-68.
41. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ. Enhanced risk for Alzheimer’s disease in person with type 2 diabetes and apoe4: The cardiovascular health study cognition study. Arch Neuol 2008 Jan; 65(1): 89-93.
42. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2008 Jul 16; 3: CD002854.
43. Kawas CH. Clinical practice. Early Alzheimer’s disease. N Engl J Med 2003 Sep 11; 349(11): 1056-63.
44. Knopman DS, Boeve BF, Peterson RC. Essentials of the proper diagnosis of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 2003 Oct; 78(10): 1290-308.
45. Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998; 116: 331.
46. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998; 150: 296-304.
47. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders-time for clinical translation? J Clin Invest 2010; 120(1): 29-40.
48. Lott IT, Head E. Alzheimer’s disease and Down syndrome: Factors in pathogenesis. Neurobiology of Aging 2005; 26: 383-89.
49. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985 Aug; 89(2): 484-90.
50. Maurer Konrad, et al. Auguste D and Alzheimer’s disease. Lancet 1997; 349: 1546-49.
51. McCurry SM, et al. Nighttime insomnia treatment and education for Alzheimer’s disease: A randomized, controlled trial. J Am Geriatr Soc 2005 May; 53(5): 793-802.
52. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984 Jul; 34(7): 939-44.
53. McShane R, et al. Memantine for dementia. Cochrane Database Syst Rev 2006 Apr 19; 2: CD003154.
54. Medivation. Pfizer and Medivation Announce Results from Two Phase 3 Studies in Dimebon (Latrepirdine*) Alzheimer’s Disease Clinical Development Program, 2010, accessible at http://investors.medivation.com/releasedetail.cfm?ReleaseID=448818.
55. National Institute on Aging, accessible at http://www.nia.nih.gov/Alzheimers/Publica tions/Unraveling/Part1/.
56. Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Education and dementia: What lies behind the association? Neurology 2007 Oct 2; 69(14): 1442-50.
57. Nicola Lautenschlager, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer’s disease. JAMA 2008; 300: 1027.
58. Phung TK, Andersen BB, Hogh P, Kessing LV, Mortensen PB, Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007; 24(3): 220-28. Epub 2007 Aug 10.
59. Qaseem A, et al. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008 Mar 4; 148(5): 370-78.
60. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010; 362: 329-44.
61. Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Medicine 2009; 7: 7.
62. Rapp SR, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28; 289(20): 2663-72.
63. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003 Apr 3; 348(14): 1333-41.
64. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer’s disease and vascular dementia. Arch Neurol 2004 May; 61(5): 705-14.
65. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta-amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg, Psychiatry 1994 57: 419-25.
66. Rowe MA, et al. Persons with dementia who become lost in the community: A case study, current research, and recommendations. Mayo Clin Proc 2004 Nov; 79(11): 1417-22.
67. Rudelli R, Strom JO, Welch PT, Ambler MW. Post-traumatic premature Alzheimer’s disease. Arch Neuro 1982 Sep; 39(9): 570-75.
68. Salloway S, Sperling R, MD, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. For the Bapineuzumab 201 clinical trial investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer’s disease. Neurology 2009; 73: 2061-70.
69. Sampson EL, et al. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev 2009 Apr 15; 2: CD007209.
70. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43: 1467-72.
71. Scarmeas N, et al. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009 Feb; 66(2): 216-25.
72. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009; 302(6): 627-37.
73. Schneider JA. High blood pressure and microinfarcts: A link between vascular risk factors, dementia, and clinical Alzheimer’s disease. J Am Geriatr Soc 2009 Nov; 57(11): 2146-47.
74. Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005 Oct 19; 294(15): 1934-43.
75. Schulz R, Beach SR, Lind B, Martire LM, Zdaniuk B, Hirsch C, Jackson S, Burton L. Involvement in caregiving and adjustment to death of a spouse: Findings from the caregiver health effects study. JAMA, 2001 June 27; 285(24): 3123-9.
76. Sink KM, et al. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005 Feb 2; 293(5): 596-608.
77. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kiyipelto M. Serum cholesterol changes after midlife and late-life cognition: Twentyone-year follow-up study. Neurology 2007 Mar 6; 68(10): 751-56.
78. Stephen R. Rapp, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA 2003; 289: 2663.
79. Stern Y, Gurland B, Taternichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994 Apr 6; 271(13): 1004-10.
80. Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer’s disease and common age-related disorders. J Clin Invest 1999; 104: 1175-79.
81. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-24.
82. Thomas, Evan. “Questions of Aged and Competence.” Time, October 22, 1984, page 3.
83. U.S. Census Bureau. “U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin: 2000-2050" in Population Projections, accessible at: http://www.census.gov/popula tion/www/projections/usinterimproj/.
84. Van Den Heuvel C, Thornton E, Vink R. Traumatic brain injury and Alzheimer’s disease: A review. Progress in Brain Research 2007; 161: 303-16.
85. Watkins PB, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994 Apr 6; 271(13): 992-98.
86. Wierenga CE, Bondi MW. Use of functional magnetic resonance imaging in the early identification of Alzheimer’s disease. Neuropsychol Rev 2007; 17: 127-43.
87. Wilson RS, Li Y, Aggarwal NT, Barnes LL, McCann JJ, Gilley DW, Evans DA. Education and the course of cognitive decline in Alzheimer disease. Neurology 2004 Oct 12; 63(7): 1198-202.
88. World Health Organization, Alzheimer’s Disease: The Brain Killer, accessible at http://www.searo.who.int/EN/Section1174/Section1199/Section1567/Section1823_ 8066.htm.
89. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, Leirer VO: Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research 1983; 17: 37-49.